We propose to leverage the multicenter international BVMC HHT recruitment network and the BVMC HHT database, in the next funding cycle, to characterize the risk of intracranial hemorrhage (ICH) in HHT patients with BAVMs and subgroups. To do so, we propose to expand the cohort of HHT BAVM patients, building on our established multicenter HHT BAVM database, the largest such cohort in the world. By doubling the cohort size and extending natural history follow-up, in Aim 1 we will increase precision of ICH rates in HHT BAVM patients overall, as well as subgroups of patients, and bring these estimates into a relevant range for clinical decision making.
In Aim 2, we propose to investigate genetic modifiers of HHT and BAVM phenotypes, building on preliminary evidence from the first BVMC cycle. We demonstrated that the ALK1 variant IVS3-35A>G is associated with HHT disease severity (presence of any organ AVMs), particularly in patients with an ENG mutation. We therefore postulate a second-hit or trans-heterozygosity hypothesis, which states that in addition to the disease-causing mutation, further reduction of function in the TGFBeta/BMP9 signaling pathway exacerbates HHT phenotypes. To test this hypothesis, we will evaluate common variants in pathway genes for their association with (1) "any AVMs" and (2) BAVM risk in HHT patients and explore associations with ICH risk and other HHT severity phenotypes. We will utilize the initial BVMC HHT cohort (n=800, 200 BAVM) for discovery and the new second-cycle HHT cohort of 800 for replication.
Aim 3 is an exploratory aim, in which we plan to study vessel wall inflammation in BAVMs and ICH, using vessel wall imaging and tissue review for inflammatory cells and mediators. Project 3 participants will be recruited through 12 HHT Centers of Excellence, as well as the Patient Support Organization, HHT Foundation International (HHTFI). The HHT investigator group will continue to work closely with the HHTFI, as well as with the DMCC, leveraging the established DMCC web-based portal, data collection and management protocols in place. The BVMC HHT Project will continue to provide a much-needed and valuable resource for the clinical neurovascular community for the study of BAVMs in HHT.

Public Health Relevance

Hereditary Hemorrhagic Telangiectasia (HHT) is a rare genetic disorder characterized by arteriovenous malformations (AVMs) in the brain, lung, and liver. Clinical care for people with brain AVMs (BAVMs) remains a challenge, with devastating intracranial hemorrhage (ICH) an ongoing reality. Quantitative information about the risks of ICH from BAVMs in HHT patients is needed to guide clinical decision-making and therapeutic trials in these patients;Project 3 will characterize these risks, as well as their determinants.

National Institute of Health (NIH)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Choquet, Hélène; Nelson, Jeffrey; Pawlikowska, Ludmila et al. (2014) Association of cardiovascular risk factors with disease severity in cerebral cavernous malformation type 1 subjects with the common Hispanic mutation. Cerebrovasc Dis 37:57-63
Reidy, Teressa Garcia; Suskauer, Stacy J; Bachur, Cathy D et al. (2014) Preliminary reliability and validity of a battery for assessing functional skills in children with Sturge-Weber syndrome. Childs Nerv Syst 30:2027-36
Cheng, Kyle H Y; Mariampillai, Adrian; Lee, Kenneth K C et al. (2014) Histogram flow mapping with optical coherence tomography for in vivo skin angiography of hereditary hemorrhagic telangiectasia. J Biomed Opt 19:086015
Lance, Eboni I; Sreenivasan, Aditya K; Zabel, T Andrew et al. (2013) Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. J Child Neurol 28:213-8
Sreenivasan, Aditya K; Bachur, Catherine D; Lanier, Kira E et al. (2013) Urine vascular biomarkers in Sturge-Weber syndrome. Vasc Med 18:122-8
Lopez, Jonathan; Yeom, Kristen W; Comi, Anne et al. (2013) Case report of subdural hematoma in a patient with Sturge-Weber syndrome and literature review: questions and implications for therapy. J Child Neurol 28:672-5
Siddique, Laila; Sreenivasan, Aditya; Comi, Anne M et al. (2013) Importance of utilizing a sensitive free thyroxine assay in Sturge-Weber syndrome. J Child Neurol 28:269-74
Arora, Karun S; Quigley, Harry A; Comi, Anne M et al. (2013) Increased choroidal thickness in patients with Sturge-Weber syndrome. JAMA Ophthalmol 131:1216-9
Shirley, Matthew D; Tang, Hao; Gallione, Carol J et al. (2013) Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 368:1971-9
Lo, Warren; Marchuk, Douglas A; Ball, Karen L et al. (2012) Updates and future horizons on the understanding, diagnosis, and treatment of Sturge-Weber syndrome brain involvement. Dev Med Child Neurol 54:214-23

Showing the most recent 10 out of 11 publications